Learn how AbbVie could help you save on HUMIRA.
Call 1.800.4HUMIRA or clickclick to learn more
▸
Results With HUMIRA
In one clinical study, 18.5% of patients with moderate to severe ulcerative colitis (UC) achieved remission as early as 8 weeks versus 9.2% on placebo. In a second study, 16.5% of patients achieved remission on HUMIRA at 8 weeks versus 9.3% on placebo. Individual results may vary.
A controlled study of 494 patients included those who were new to a biologic as well as those who had taken a biologic treatment in the past. At week 52, 17.3% were in remission with HUMIRA compared to 8.5% taking placebo. Individual results may vary.
Common side effects with HUMIRA include:
- injection site reactions: redness, rash, swelling, itching, or bruising. These symptoms usually will go away within a few days. Call your doctor right away if you have pain, redness or swelling around the injection site that does not go away within a few days or gets worse
- upper respiratory infections (including sinus infections)
- headaches
- rash
Having my symptoms under control meant I didn’t have to worry about where the nearest restroom was whenever I went out.
– Maria, a real UC patient using HUMIRA
Wondering what it’s like to be in remission? Hear from HUMIRA patients who know.
HUMIRA Complete provides access to a variety of resources
|
|
|
|
|
Have insurance coverage questions?To help you get off to a good start with your HUMIRA prescription, Insurance Specialists are available to help you understand your HUMIRA coverage. |
|
|
Has COVID-19 made paying for your medicine a challenge?AbbVie may be able to help. Call 1.800.4HUMIRA |
*Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.
US-HUMG-210358
